Medtronic stock (IE00BTN1Y115): focus on diabetes spin-off and latest quarterly results

Medtronic is reshaping its portfolio with the proposed spin-off of its patient monitoring and respiratory interventions business while reporting solid quarterly figures. What does this mean for the medical technology group’s revenue mix and its role for US healthcare investors?

Medtronic is in the spotlight after reporting its fiscal 2025 third-quarter results and advancing plans to spin off its patient monitoring and respiratory interventions business into a separate listed company called Empirion, according to a company press release dated 02/18/2025 and subsequent updates on 03/06/2025 from Medtronic’s investor information pages (Medtronic newsroom as of 02/18/2025; Medtronic newsroom as of 03/06/2025). The move is intended to create a more focused portfolio centered on higher-growth cardiovascular, neuroscience, diabetes and surgical technologies.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Medtronic plc
• Sector/industry: Medical technology, healthcare
• Headquarters/country: Dublin, Ireland
• Core markets: United States, Europe, global hospital and outpatient care
• Key revenue drivers: Cardiovascular devices, surgery, neuroscience, diabetes technologies
• Home exchange/listing venue: New York Stock Exchange (ticker: MDT)
• Trading currency: US dollar (USD)

Medtronic: core business model

Medtronic operates as a diversified medical technology group supplying devices and systems that are primarily used in hospitals, physician practices and outpatient centers. The company organizes its activities into several operating segments such as Cardiovascular, Medical Surgical, Neuroscience and Diabetes, which together span a broad range of therapeutic areas. This diversification helps Medtronic address chronic diseases with products that are often used in life-sustaining or minimally invasive procedures.

The cardiovascular portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac resynchronization therapy devices, transcatheter heart valves and other products aimed at treating heart rhythm disorders and structural heart disease. These solutions support physicians in managing high-risk patients and are often implanted for many years, leading to a mix of initial device sales and recurring service revenue. Given the high prevalence of cardiovascular disease in the United States, this area remains a central pillar of Medtronic’s business.

Medtronic’s Medical Surgical and Neuroscience segments cover technologies for soft-tissue surgery, robotic-assisted procedures, spinal and cranial implants as well as pain therapy and neuromodulation systems. These systems enable surgeons to perform minimally invasive operations and provide more targeted therapy for disorders such as chronic pain or movement disorders. In parallel, the Diabetes segment develops insulin pumps, continuous glucose monitoring systems and integrated platforms designed to make the daily management of diabetes more automated and data-driven.

Main revenue and product drivers for Medtronic

Medtronic’s revenue is driven by a large installed base of devices and ongoing innovation in high-value product lines. In its fiscal 2025 third quarter, the company reported revenue of approximately 8.7 billion USD, essentially flat year-over-year on a reported basis but higher on an organic basis, according to the company’s results release for the quarter ended 01/24/2025 published on 02/18/2025 (Medtronic newsroom as of 02/18/2025). Management highlighted particular strength in cardiovascular and neuroscience therapies, while some areas continued to face pricing and competitive pressure.

The diabetes franchise is another important revenue contributor, with Medtronic focusing on advanced insulin delivery systems that integrate continuous glucose monitoring and algorithms for automated insulin dosing. The company has been rolling out new-generation insulin pump platforms in key markets and working on regulatory approvals in the United States to expand access. Because diabetes is a long-term condition, this business can generate recurring revenue through pump disposables, sensors and software services once patients are on the platform.

In the United States, procedure volumes, hospital capital budgets and insurance reimbursement policies influence demand for Medtronic’s devices. A return toward more normalized procedure volumes after pandemic-related disruptions has supported utilization of implants and surgical systems. At the same time, the group has been investing in its surgical robotics platform and next-generation cardiac and neuro devices to maintain or grow share in competitive categories, particularly against other large medtech players that are also targeting US hospital customers.

Strategic spin-off of Empirion and portfolio focus

A key strategic step is Medtronic’s plan to separate its patient monitoring and respiratory interventions activities into an independent company named Empirion. The group announced the intended spin-off and later revealed the name and branding on 03/06/2025, indicating that Empirion would focus on acute care monitoring, respiratory support and other hospital technologies that are somewhat different from Medtronic’s remaining portfolio, according to the company’s branding announcement (Medtronic newsroom as of 03/06/2025). The move is intended to create two more focused businesses with distinct strategic priorities and capital allocation approaches.

For Medtronic, the spin-off is expected to sharpen its emphasis on therapies that are closely tied to chronic disease management and complex interventions, such as cardiac devices, neuromodulation solutions and diabetes technologies. Management has communicated that a more streamlined portfolio should allow for targeted investment in innovation and commercial execution in fewer therapeutic areas. While specific terms of the transaction may evolve before completion, the plan suggests that Medtronic is seeking to improve its growth profile by prioritizing categories where it sees the strongest demand and technology pipeline.

The proposed Empirion entity, meanwhile, would be positioned to focus on monitoring systems, ventilators and related technologies used primarily in intensive care and operating rooms. From the perspective of Medtronic shareholders, the separation could provide greater transparency into the performance of both the retained businesses and the spun-off company. It could also change the risk and growth profile of Medtronic’s remaining portfolio, depending on how investor perception of the different end markets and capital intensity develops over time.

Why Medtronic matters for US investors

Although Medtronic is legally headquartered in Ireland, the company generates a significant share of its revenue in the United States and is listed on the New York Stock Exchange under the ticker MDT. For US investors, this means the stock is easily accessible via major trading platforms and denominated in US dollars, reducing foreign-exchange frictions relative to many overseas medical technology names. The group is also part of widely followed healthcare and medtech indices, making it relevant for sector-focused strategies.

Medtronic’s exposure to structural healthcare trends in the United States supports its long-term relevance. Aging demographics, high rates of chronic disease and the expansion of value-based care models all drive demand for devices that can improve outcomes or reduce hospital stays. The company’s broad portfolio, from pacemakers and defibrillators to insulin pumps and advanced surgical tools, delivers products that integrate into US hospital workflows and reimbursement structures. This integration can create switching costs for providers, potentially stabilizing demand even amid pricing pressure.

At the same time, US investors need to keep in mind that regulatory developments, reimbursement decisions and capital spending cycles in the American healthcare system can influence Medtronic’s performance. Approvals from agencies such as the US Food and Drug Administration can open up new revenue opportunities for devices, while delays or additional data requirements can push out product launches. Hospital budget constraints, particularly during periods of economic uncertainty, may also impact the pace at which new technologies are adopted.

Conclusion

Medtronic is navigating a period of portfolio reshaping while continuing to report sizeable quarterly revenue from its diversified medical technology franchises. The planned spin-off of the patient monitoring and respiratory interventions business into Empirion is intended to sharpen strategic focus and may alter the growth and risk profile of the remaining company. For US investors following large-cap healthcare names, Medtronic remains closely linked to trends in chronic disease treatment, hospital procedure volumes and regulatory decisions in the American market. As always, the stock’s potential must be weighed against competitive dynamics, pricing and execution risks in its key product categories.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.